Galectin Therapeutics
GALT
26 hedge funds and large institutions have $10.4M invested in Galectin Therapeutics in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
230% more capital invested
Capital invested by funds: $3.14M → $10.4M (+$7.24M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
63% more funds holding
Funds holding: 16 → 26 (+10)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $204K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
+$1.03M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$493K |
| 3 |
BCA
Benchmark Capital Advisors
New York
|
+$307K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$217K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFCP
Twin Focus Capital Partners
Boston,
Massachusetts
|
-$519K |
| 2 |
Neuberger Berman Group
New York
|
-$45.9K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.01K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$1.01K | -150 | -60% |
|
GALT Hedge Fund Activity: Q3 2013 in Review
26 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2013, worth a combined $10.4M — up 230% from $3.14M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GALT positions and 2 closed out — a net gain of 10 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was EAM Investors, opening a new position worth an estimated $1.03M. The largest seller was Twin Focus Capital Partners, cutting an estimated $519K.
- 26 institutional investors held Galectin Therapeutics (GALT) as of Q3 2013, up from 16 in Q2 2013.
- Funds reported $10.4M of Galectin Therapeutics stock for Q3 2013, up 230% quarter-over-quarter.
- 12 funds opened new Galectin Therapeutics positions in Q3 2013 and 2 closed out, a net change of +10 holders.
- The largest Galectin Therapeutics buyer in Q3 2013 was EAM Investors, an estimated $1.03M added.
- The largest Galectin Therapeutics seller in Q3 2013 was Twin Focus Capital Partners, an estimated $519K sold.
Based on aggregated 13F filings for Q3 2013.